Coming Soon·Opens soon·Synced from source July 6, 2026
Studies Addressing Rare Neurodegenerative Diseases including ALS
Food and Drug Administration
Posted
Oct 23, 2025
Closes
No deadline published by the funder
Last verified
Jul 6, 2026
Classification and identifiers
- Solicitation number
- FOR-FD-25-006
- Assistance listing (CFDA)
- 93.103
Amount
Amount not published by the funder
Who can apply
NonprofitsLocal governmentsCounty governmentsPrivate universitiesNonprofits (non-501c3)For-profits
About this opportunity
The purpose of this funding opportunity announcement (FOA) is to support studies that advance medical product development of interventions intended to prevent, diagnose, mitigate, treat, or cure ALS and other rare neurodegenerative diseases in adults and children. Through the support of these studies, FDA expects to address critical knowledge gaps, exert a significant impact on rare neurodegenerative diseases, and to inform current or future product development.
Related opportunities
- Clinical Trials Addressing Unmet Needs of Rare Neurodegenerative Diseases (R01) Clinical Trials RequiredFood and Drug AdministrationUp to $900K
- Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)National Institutes of HealthCloses Nov 2026
- Functional Target Validation for Alzheimer's Disease-Related DementiasNational Institutes of Health
- Clinical Studies of Orphan Products Addressing Unmet Needs of Rare Diseases (R01 Clinical Trials Required)Food and Drug Administration
- Efficient and Innovative Natural History Studies Addressing Unmet Needs in Rare Diseases (R01 Clinical Trials Optional)Food and Drug AdministrationUp to $400K
- Interdisciplinary Research to Understand the Complex Biology of Resilience to Alzheimer’s and Related Dementias Disease RiskNational Institutes of Health
Finding similar opportunities...